If my LDL-C is “normal,” am I safe?

Not always. LDL-C measures the weight of cholesterol, not how many particles are carrying it. If your triglycerides are high and your HDL is low (a Trig/HDL ratio above 1.5), you likely have phenotype B (many small, dense LDL particles) and high ApoB – meaning higher risk even with “normal” LDL. Ask your doctor for an ApoB test.

Is a statin the only answer?

Statins (cholesterol-lowering drugs) work well and are the right choice in some cases – that is a decision for you and your doctor. But lifestyle changes (diet, movement, sleep, insulin sensitivity – how well your cells respond to insulin) can improve particle number, particle size, and inflammation as much as a drug alone, and they work well together with statins.

Can Lp(a) be treated?

Lifestyle changes barely affect Lp(a) (a genetic, LDL-like particle linked to heart risk). If your Lp(a) is high, the focus shifts to controlling everything else more strictly: LDL/ApoB, hs-CRP, blood pressure, and smoking. New RNA-based drugs are being tested in clinical trials.

How important are homocysteine and fibrinogen?

They are not the main markers. Guidelines rely on LDL-C, non-HDL and ApoB; the link between homocysteine or fibrinogen and risk is relatively weak, and lowering them has not shown independent benefit. They are measured selectively – for example with suspected vitamin deficiency, or early atherosclerosis or thrombosis in the family – and always interpreted together with the rest of the picture.

Should I get a coronary artery calcium (CAC) scan?

A CAC scan (which measures calcium buildup in the heart’s arteries) is mainly considered when risk is borderline and the result could genuinely change a treatment decision. A score of 0 suggests low risk over the coming years; a higher score is a reason to discuss more active prevention with your doctor. It is not a test for everyone, and the decision is made individually.

Miks LDL üksi ei ole piisav marker?

LDL-kolesterool näitab kolesterooli hulka, mitte osakeste arvu. Kahel sama LDL-iga inimesel võib risk olla erinev, kui ühel on palju väikeseid tihedaid osakesi. ApoB näitab osakeste arvu ja täpsustab riski.

Mis on ApoB ja miks see loeb?

ApoB (apolipoproteiin B) on valk igal aterogeensel osakesel (LDL, VLDL, IDL, Lp(a)). Üks osake = üks ApoB. ESC/EAS juhendid soovitavad kasutada ApoB-d riski täpsustamiseks, eriti kõrgete triglütseriidide, diabeedi ja ülekaalu korral. Sihtväärtus sõltub üldisest riskist.

Millal tasub lasta mõõta Lp(a)-d?

Juhendite (ESC/EAS) järgi vähemalt üks kord elu jooksul igal täiskasvanul. Lp(a) tase on suures osas pärilik – kui vanematel oli varane infarkt, aruta mõõtmist arstiga. Kõrge Lp(a) suurendab südame-veresoonkonna haiguste riski.

Kas vähese süsivesikusisaldusega toitumine tõstab LDL-i ja kas see on ohtlik?

Osal inimestel tõuseb vähese süsivesikusisaldusega toitumisel LDL-kolesterool märgatavalt, eriti saledatel ja aktiivsetel. Samal ajal võivad triglütseriidid langeda ja HDL tõusta. Riski hindamiseks vaata ApoB-d ja tervikpilti ning aruta tulemust arstiga.

Kas statiin on ainus lahendus kõrge kolesterooli puhul?

Ei, kuid statiin on üks paremini uuritud ravimeid. Lisaks kasutatakse teisi ravimeid (nt esetimiib) ning elustiili muutusi: kiudained, taimsed steroolid, oomega-3. Punase riisi pärm toimib statiiniga sarnaselt ja seda ei tohi koos statiiniga võtta. Ravi valib arst üldise riski ja taluvuse põhjal.

Millised toidud alandavad LDL-i tõenduspõhiselt?

Lahustuvad kiudained (kaerakliid, chia, oad), pähklid, oliiviõli, avokaado, taimsed steroolid ja rasvane kala. Mitme sellise toidu koosmõjul on uuringutes LDL märgatavalt langenud (nn portfoolio-dieet, Jenkins jt).

Kas munad tõstavad kolesterooli?

Enamikul inimestel mõjutavad munad vere kolesterooli vähe, sest maks reguleerib oma kolesteroolitootmist. Osal inimestel tõuseb LDL toidukolesterooli mõjul rohkem. Kui sööd palju mune, kontrolli lipiide.

Mis on „aterogeenne diabeetiline düslipideemia“?

Insuliiniresistentsuse tüüpiline pilt: kõrged triglütseriidid, madal HDL, väikesed tihedad LDL-osakesed ja kõrgem ApoB. LDL üksi võib olla „normis“, kuid risk on suurem. Seepärast on insuliiniresistentsuse ja kolesterooli teemad omavahel seotud.

Kas oomega-3 lisandid vähendavad kardiovaskulaarriski?

Puhta EPA preparaadiga uuringus (REDUCE-IT) vähenesid südame-veresoonkonna sündmused, kuid EPA ja DHA segupreparaatide uuringute tulemused on vastuolulised. Suuri annuseid (2–4 g päevas) kasuta ainult koos arstiga.

Millal on homotsüsteiini mõõtmine põhjendatud?

Homotsüsteiin ei kuulu rutiinsesse südameriski hindamisse – ravijuhendid tuginevad LDL-ile, non-HDL-ile ja ApoB-le. Mõõtmine on põhjendatud valikuliselt: B12 või folaadi puuduse kahtlusel, varajase ateroskleroosi või tromboosi korral peres, teatud neeru- ja kilpnäärmehaiguste puhul. Kõrgenenud tase on riskimarker, kuid selle alandamine B-vitamiinidega ei ole uuringutes infarktiriski kindlalt vähendanud.

Academy

Heart & vascular health

Cholesterol, ApoB and the lipoprotein profile

“High cholesterol” is one of the most misunderstood results in modern medicine. International guidelines (ESC/EAS) put LDL-C, non-HDL cholesterol and ApoB at the centre – these have the strongest causal evidence for atherosclerosis. Lp(a), hs-CRP, metabolic markers and body weight add context. Any single number only means something in context: age, sex, family history, blood pressure, smoking, insulin sensitivity and existing conditions.

LDL-C, non-HDL and ApoB are the guideline-level target markers
ApoB refines risk especially with high triglycerides or a “normal” LDL
Lp(a) and hs-CRP refine risk; homocysteine and fibrinogen are selective add-ons

See webinars 5 tests for metabolic health

Arst vaatab laiendatud lipiidipaneeli tulemusi

What cholesterol is – and why the standard test misses half the picture

Cholesterol is not a “bad substance.” It’s the raw material for every cell membrane, for hormones like testosterone, estrogen, and cortisol, and for vitamin D. Your liver makes about 80% of the cholesterol in your blood; only about 20% comes from food.

Cholesterol doesn’t dissolve in water, so it travels through the blood inside carrier particles called lipoproteins – LDL, VLDL, IDL, HDL, and Lp(a). Every one of these particles carries a protein called apolipoprotein B (ApoB) on its surface, except HDL, which carries ApoA instead. Measuring ApoB tells you exactly how many artery-clogging particles you have – something the standard “LDL cholesterol” number (measured in weight) cannot show.

Two people can have the same LDL-C (say 3.5 mmol/L) but very different risk. One may have large, fluffy LDL particles in small numbers (phenotype A – lower risk). The other may have many small, dense LDL particles (phenotype B – higher risk). Same amount of cholesterol, very different risk.

Warning signs and a higher-risk profile

Trig/HDL ratio above 1.5 – an indirect sign of phenotype B (small, dense LDL) and insulin resistance
Family history of an early heart attack (before 55 in men, before 65 in women)
Diagnosed familial hypercholesterolemia (FH – an inherited condition that causes very high cholesterol)
Xanthelasma (yellow patches on the eyelids) or a gray ring around the cornea before age 50
Thickening of the arteries seen on a carotid or abdominal ultrasound
Metabolic syndrome: extra belly fat, high blood pressure, and insulin resistance together
An ongoing inflammatory condition (autoimmune disease, gum disease, inflammatory bowel disease)
Smoking and chronic stress – both speed up atherosclerosis (plaque buildup) even with “normal” LDL

Why ApoB matters more than LDL-C

A plaque starts to form when a particle carrying ApoB (a protein tag on artery-clogging particles) gets stuck in the artery wall. What matters is how many particles are knocking at the door – not how many grams of cholesterol they carry. Every LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule, so counting ApoB gives you a direct particle count.

Large studies (Sniderman, Circulation 2019; INTERHEART) show that ApoB predicts heart attacks and strokes more accurately than LDL-C. This matters most when the two disagree: someone with “normal” LDL-C but high ApoB is still at high risk.

Particle size: phenotype A vs. phenotype B

Phenotype A – larger, fluffier LDL particles, fewer of them, lower risk
Phenotype B – small, dense LDL particles (sdLDL), more of them, higher risk
Phenotype B tends to appear with insulin resistance, high triglycerides, and low HDL
A Trig/HDL ratio above 1.5 (mmol/L) or 3.5 (mg/dL) is a strong sign of phenotype B
Small, dense LDL particles slip into the artery wall more easily and oxidize (break down chemically) more easily too – both make them more dangerous

Four pillars for a healthier lipid profile

A statin (cholesterol-lowering drug) is just one tool. Lifestyle works alongside it and directly changes particle number, particle size, and inflammation.

Nutrition

Cut back on refined carbs and sugary drinks – the biggest drivers of high triglycerides and phenotype B (small, dense LDL particles). Eat more fiber (30+ g a day), omega-3 fats, and monounsaturated fats (olive oil, avocado, nuts). Losing 5–10% of your body weight often lowers ApoB (particle count) by 15–25%.

Insulin sensitivity

Phenotype B and high triglycerides are usually caused by insulin resistance (when cells respond poorly to insulin). Lowering insulin levels – through an 8–10 hour eating window, strength training, and good sleep – can improve your lipid profile more than medication alone.

Supplements that can support your lipids and blood vessels

Supplements don’t replace statins (cholesterol-lowering drugs) when your doctor says you need one. But several can support healthy lifestyle changes and improve markers that statins don’t touch.

Omega-3 (EPA/DHA fatty acids, 2–4 g/day) – lowers triglycerides by 20–30% and reduces inflammation
Berberine – lowers LDL-C and ApoB (particle count) by about 15% and improves insulin sensitivity; check for drug interactions first
Red yeast rice (contains monacolin K) – works like a statin; don’t combine it with an actual statin
B12, folate, B6 – lower homocysteine levels, but trials have not shown that this alone reduces heart attack risk; used mainly for a confirmed deficiency
Vitamin K2 – calcium metabolism is under study, but evidence for cardiac risk is still limited
CoQ10 – mainly discussed for muscle complaints on statins; the evidence is mixed
Nattokinase – effects on clotting markers are preliminary; do not combine with blood-thinning medication without discussing it with your doctor
Plant sterols and fiber (such as psyllium) – reduce how much cholesterol your gut absorbs

Fasting and your lipid profile

Time-restricted eating (eating only within a set window each day) and periodic fasting can lower triglycerides, shift LDL toward the safer phenotype A, and lower ApoB. This likely happens because fasting improves insulin sensitivity (how well your cells respond to insulin).

In a 2019 study (Tinsley et al., Am J Clin Nutr), an 8-hour eating window combined with strength training improved the lipid profile and body composition in adults with excess weight, including triglycerides and fat mass.

Fasting is not right for everyone. Avoid it during pregnancy or breastfeeding, if you have a history of an eating disorder, or if you take certain medicines (like insulin or sulfonylureas) without medical supervision.

See the study (Am J Clin Nutr)

Which tests to discuss with your doctor

LDL-C, HDL-C, triglycerides, total cholesterol – the base panel everything starts from
Non-HDL cholesterol – a calculated value covering all atherogenic particles
ApoB – particle count; especially useful with high triglycerides, diabetes or excess weight (the target depends on risk level)
Lp(a) – usually one measurement in a lifetime is enough
Trig/HDL ratio – an indirect hint about metabolic status
hs-CRP – a risk modifier; interpreted only in the absence of acute infection
Fasting glucose, HbA1c, insulin/HOMA-IR – help show the metabolic background (interpretation is context-dependent)
Thyroid (TSH) – an underactive thyroid can raise LDL
Kidney function, liver markers, vitamin D, ferritin – overall picture and treatment safety
Homocysteine, fibrinogen – selective add-ons when clinically justified, not routine screening
Coronary artery calcium (CAC) – considered when risk is borderline and the result could change a treatment decision

The rest is hidden

Free

Read the full article

Enter your email and the full text opens right here on this page.

Go deeper: lipidology and cardiovascular webinars

Recorded webinars on ApoB, lipoproteins and cardiovascular risk assessment – with Dr Saadi.

See webinars

Lipiidiprofiili sihttasemed

Sihtväärtused sõltuvad kardiovaskulaarsest riskist (ESC 2019, EAS 2022)

Marker	Madal risk	Mõõdukas / kõrge risk	Väga kõrge risk
LDL-kolesterool	< 3,0 mmol/l	< 2,6 mmol/l	< 1,4 mmol/l
ApoB	< 100 mg/dl	< 80 mg/dl	< 65 mg/dl
Triglütseriidid	< 1,7 mmol/l	< 1,5 mmol/l	< 1,5 mmol/l
HDL-kolesterool (M / N)	> 1,0 / > 1,2 mmol/l	sama	sama
Lp(a)	< 30 mg/dl (< 75 nmol/l)	sama	sama
Non-HDL kolesterool	< 3,8 mmol/l	< 3,4 mmol/l	< 2,2 mmol/l
Homotsüsteiin (valikuline lisanäitaja)	labori referentsvahemik	sama	sama

LDL-kolesterool

Madal risk: < 3,0 mmol/l
Mõõdukas / kõrge risk: < 2,6 mmol/l
Väga kõrge risk: < 1,4 mmol/l

ApoB

Madal risk: < 100 mg/dl
Mõõdukas / kõrge risk: < 80 mg/dl
Väga kõrge risk: < 65 mg/dl

Triglütseriidid

Madal risk: < 1,7 mmol/l
Mõõdukas / kõrge risk: < 1,5 mmol/l
Väga kõrge risk: < 1,5 mmol/l

HDL-kolesterool (M / N)

Madal risk: > 1,0 / > 1,2 mmol/l
Mõõdukas / kõrge risk: sama
Väga kõrge risk: sama

Lp(a)

Madal risk: < 30 mg/dl (< 75 nmol/l)
Mõõdukas / kõrge risk: sama
Väga kõrge risk: sama

Non-HDL kolesterool

Madal risk: < 3,8 mmol/l
Mõõdukas / kõrge risk: < 3,4 mmol/l
Väga kõrge risk: < 2,2 mmol/l

Homotsüsteiin (valikuline lisanäitaja)

Madal risk: labori referentsvahemik
Mõõdukas / kõrge risk: sama
Väga kõrge risk: sama

Väga kõrge risk = varasem infarkt/insult, diabeet koos elundikahjustusega, krooniline neeruhaigus, familiaalne hüperkolesteroleemia. Sihtväärtused on juhendite üldised orientiirid ja neid kohandatakse alati individuaalselt. LDL, non-HDL ja ApoB on peamised sihtnäitajad; homotsüsteiin on valikuline lisanäitaja ilma üldise ravieesmärgita.

Frequently asked questions

Go deeper: related materials

Articles

Guides

Webinars

All webinars

Courses

All courses

Dr Sergey Saadi – expert in advanced lipidology and metabolic health

Dr Sergey Saadi is a physician with over 15 years of clinical practice.

Clinical approach: guideline core markers (LDL, non-HDL, ApoB) together with the full risk profile and metabolic context
Regular speaker in media and in clinician training
Author of “Dangerous secrets of blood sugar” (Varrak)

This page is educational and general. It is not personal medical advice, a diagnosis or a treatment plan. Discuss changes with your doctor.